[Association between RIPK4 relative copy number and prognosis of colorectal cancer patient after oxaliplatin-based chemotherapy].

Abstract

OBJECTIVE:

To investigate the association between receptor-interacting kinase protein 4 (RIPK4) relative copy number (RCN) and prognosis of stage III( colorectal cancer (CRC) patients treated with oxaliplatin-based chemotherapy.

METHODS:

RIPK4 RCN was determined by real-time PCR and then dichotomized into high RIPK4 RCN group(n=35) and low RIPK4 RCN group (n=104) using the third quartile as the cut-off point. Overall survival (OS) and recurrence-free survival (RFS) were compared between high and low RIPK4 RCN groups. The subgroup prognostic analysis was also conducted based on tumor site.

RESULTS:

The median follow-up period was 49 months (ranged 4 to 98 months). Patients with high RIPK4 RCN had poorer OS than those with low RIPK4 RCN, which reached marginal significance(median OS, 43.0 months vs. 53.5 months, P=0.074). Meanwhile there was no significant difference of RFS between two groups (P=0.352). In colon cancer subgroup, high RIPK4 RCN was significantly associated with poor OS (median OS, 31.5 months vs. 56.6 months, P=0.015) but not with RFS (P=0.135). In rectal cancer subgroup, RIPK4 RCN was not associated with both OS and RFS (P=0.981, P=0.738). Multivariate analysis revealed that high RIPK4 RCN was an independent prognostic factor of OS in stage III( CRC patients treated with oxaliplatin-based chemotherapy (HR=2.903, 95% CI: 1.275 to 6.610).

CONCLUSION:

RIPK4 RCN is significantly associated with OS in stage III( colon cancer patients receiving oxaliplatin-based chemotherapy and may be a novel biomarker that can predict the efficacy of oxaliplatin in colon cancer patients.

• Authors: Kangsheng Peng, Moubin Lin, Qing Wei, Huaguang Li, Chenbo Zhang, Ruting Xie, Zhanju Liu
• Journal: Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery (Zhonghua Wei Chang Wai Ke Za Zhi) Vol. 18 Issue 11 Pg. 1111-4 (Nov 2015) ISSN: 1671-0274 [Print] China
• PMID: 26616804 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• Organoplatinum Compounds
• Oxaliplatin
• RIPK4 protein, human
• Protein Serine-Threonine Kinases
• Fluorouracil

Topics

• Antineoplastic Agents (administration & dosage)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Chemotherapy, Adjuvant
• Colorectal Neoplasms (drug therapy, genetics)
• Fluorouracil
• Gene Dosage
• Humans
• Neoplasm Staging
• Organoplatinum Compounds
• Oxaliplatin (administration & dosage)
• Prognosis
• Protein Serine-Threonine Kinases (genetics)